Famciclovir-d₄  (Synonyms: BRL 42810-d₄)

Famciclovir-d₄ is the deuterium labeled Famciclovir. Famciclovir (BRL 42810) is a guanine analogue antiviral agent used for the treatment of various herpesvirus infections[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

325.36

C₁₄H₁₅D₄N₅O₄

1020719-42-9

104227-87-4

CC(OCC(COC(C)=O)C([2H])([2H])C([2H])([2H])N1C2=NC(N)=NC=C2N=C1)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

  [2]. Harrell AW, Wheeler SM, Pennick M, Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos. 1993 Jan-Feb;21(1):18-23.  [Content Brief]

  [3]. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995 Aug;50(2):396-415.  [Content Brief]

  [4]. Trépo C, Jezek P, Atkinson G, Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol. 2000 Jun;32(6):1011-8.  [Content Brief]

  [5]. Filer CW, Ramji JV, Allen GD, Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica. 1995 May;25(5):477-90.  [Content Brief]

  [6]. Wutzler P, Ulbricht A, Färber I. Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice. Intervirology. 1997;40(1):15-21.  [Content Brief]